Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Nail Psoriasis Severity Index (NAPSI)
研究概览
简要总结
Observational, prospective and multicentre study to evaluate the effectiveness of calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to clinical practice and following the Product Data Sheet instructions, in the topical treatment of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index (NAPSI) at 12 weeks of treatment with respect to the initial score.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with nail psoriasis who start, according to clinical practice, topical treatment with calcipotriene and betamethasone dipropionate aerosol foam
- •Patients who authorize their participation in the study by signing written informed consent.
排除标准
- •Patients receiving treatment with systemic drugs or their prescription is scheduled for the next 3 months. However, may be included patients who receive the same systemic treatment regimen from at least 6 months before their inclusion in the study and up to 14 weeks later.
- •Patients with any situation or state that in the opinion of the investigator discourages their participation in the study.
研究组 & 干预措施
Patients with nail psoriasis
Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
干预措施: Calcipotriene and betamethasone dipropionate aerosol foam (Drug)
结局指标
主要结局
Nail Psoriasis Severity Index (NAPSI)
时间窗: Week 24 of treatment
Numeric, reproducible, objective, simple tool for evaluation of nail psoriasis
次要结局
- Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)(Baseline, Week 12 of treatment and Week 24 of treatment)
研究者
Angeles Florez
Head of Dermatology
Complejo Hospitalario Universitario de Pontevedra